Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

SAN DIEGO, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2009. The Company reported total revenue of $211.2 million for the third quarter, including net product sales of $192.9 million. Non-GAAP operating income was $0.6 million for the quarter ended September 30, 2009 compared to non-GAAP operating loss of $32.7 million for the same period in 2008. Net loss for the quarter ended September 30, 2009 was $26.7 million, or $0.19 per share compared to $79.0 million, or $0.58 per share for the same period in 2008. Net loss for the quarter ended September 30, 2008 included a loss on impairment of investments of $14.9 million, or $0.11 per share. At September 30, 2009 the Company held cash, cash equivalents and short-term investments of $619.7 million.

"We continue to make substantial progress toward our goal of becoming operating cash flow positive on a sustainable basis by the end of 2010, and have generated positive cash flow in the third quarter," said Mark G. Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals. "Over the next few quarters we will make incremental investments to successfully launch exenatide once weekly, which will lead to variability in our operating results, but we expect to achieve sustainable positive operating cash flow by the end of next year."

Quarter Ended September 30, 2009

Net product sales of $192.9 million for the quarter ended September 30, 2009 include $171.1 million for BYETTA® (exenatide) injection and $21.8 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $201.4 million consisting of $179.9 million for BYETTA and $21.5 million for SYMLIN for the same period in 2008. Revenues
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... XTENT, Inc.,(Nasdaq: XTNT ) today announced a ... Notified Body for CE Mark approval of its ... that recently,presented six-month follow up results from the ... Agency, which reviews the drug formulation,submission of XTENT,s ...
... Make Qnexa the New Clinical Gold, Standard Drug ... Resources, WALTHAM, Mass., June 12 Decision Resources, ... on pharmaceutical and,healthcare issues, finds that a drug that ... would earn a 40 percent patient share in,the obesity ...
Cached Medicine Technology:XTENT Announces European Regulatory Update 2XTENT Announces European Regulatory Update 3A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market 2
(Date:7/25/2014)... July 25, 2014 DON’T PAUSE is a ... uncomfortable bloating, hot flashes, mood swings, burning tongue menopause ... Dr. Shoreh Ershadi. The AntiAging Institute of California is now ... allows women to try this revolutionary product. For a limited ... get a third bottle at no charge. , ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Dietary changes can dramatically ... a daily basis, according to a new study. ... might help detect and ease flare-ups for people with ... colitis and Crohn,s disease), the researchers said. Trillions ... effect on human health isn,t well understood, the Massachusetts ...
(Date:7/25/2014)... San Francisco, Ca (PRWEB) July 25, 2014 ... in business with their Anniversary Futon Sale. The Futon Shop ... mom and pop shop, which has grown from a few ... States over 33 different kinds of futon mattresses. , ... mouth in the beginning and the desire to sleep on ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 In an election ... it’s no surprise that Americans may not be sleeping well, ... according to a new poll conducted by US-Mattress . ... from across the country, “Which Political Party Do You Side ... that those registered as Independents tout a higher rate of ...
(Date:7/25/2014)... the U.S. are living with a brain tumor, and ... factors, scientists are still searching for answers. , "Right ... and we don,t know why people develop brain tumors," ... Brain Tumor Association. "It,s frustrating for the brain tumor ... funds research to pursue answers to these questions, and ...
Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:New Study Shows the Growing Number of Independent Voters Have a Greater Propensity for Sleeping Well vs. Democrats or Republicans 2Health News:New Study Shows the Growing Number of Independent Voters Have a Greater Propensity for Sleeping Well vs. Democrats or Republicans 3Health News:Brain tumor causes and risk factors elude scientists 2
... Amilpar,(BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: ... today its consolidated,results for the fourth quarter 2007 ... financial information is presented on a consolidated basis,and ... Law and the,Accounts Chart of the Agencia Nacional ...
... 11 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Brothers Global Healthcare Conference on Wednesday, March 19,at ... a live webcast of,the presentation at:, http://cc.talkpoint.com/LEHM002/031808a_jw/default.asp?entity=OnyxPharmaceu ,tic ... on 15 minutes early in order to,register and ...
... new study in the,Journal of the American Medical ... (methicillin-resistant Staphylococus aureus), a simple,skin or nasal swab, ... Screening for Methicillin-Resistant Staphylococcus aureus at,Hospital Admission and ... 10, March 12, 2008)., The findings of ...
... 11 Eli Manning, NFL Most,Valuable Player 2008 ... New,York Giants, will address a National Press Club ... national challenge to encourage Americans to be,more active., ... the President,s Council on,Physical Fitness and Sports, Manning ...
... Inc.,(NYSE: RBN ) announced today that it will ... the period ended February 29, 2008, after,market close on ... conference,call will be held at 2:00 p.m., EDT on ... Chief Executive Officer, and Christopher M. Hix,Vice President and ...
... Center have teased out two distinct sets of risk ... are two completely different kinds of the disease. , ... caused by the human papillomavirus (HPV), a common sexually ... behaviors and marijuana use, rather than tobacco and alcohol. ...
Cached Medicine News:Health News:Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007 2Health News:JAMA Article Provides False Support for CDC's Do-Nothing Position on MRSA 2Health News:Researchers ID behavioral risk factors for head and neck cancers 2Health News:Researchers ID behavioral risk factors for head and neck cancers 3
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... is the newest real-time PCR instrument offered ... offers six detection channels that provide fluorescence ... and 710nm. Perform rapid PCR due to ... with glass capillaries. Virtually any published protocol ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
... standard in QPCR with the Mx4000 multiplex ... superior performance, more flexibility, and reasonable pricing. ... with Windows 98SE and Pentium III (or ... Speakers, Surge Protector (US only), Mx4000 Software ...
Medicine Products: